생화학분자생물학회

	Beom K. Choi( magetin@gmail.com )
	2023-present	CEO, SamdaBiolab, South Korea
	2023-present	CTO, InnobationBio, South Korea
	2019-2023	Principal Investigator, Biomedicine Production Branch, NCC, South Korea
	2018-2022	QA manager, Biomedicine Production Branch, NCC, South Korea
	2011-2019	Senior Scientist, Cancer Immunology Branch, NCC, South Korea
	2008-2011	Associate Scientist, Immune & Cell Therapy Branch, NCC, South Korea
	2000-2004	PhD, Department of Immunology and Biomedicine, University of Ulsan, South Korea
	1997-1999	MS, Department of Microbiology, Hannam University, South Korea

4-1BB immunotherapy: advances and hurdles

Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have demonstrated the involvement of 4-1BB in infection and tumor immunity. However, the clinical development of 4-1BB agonist antibodies has been impeded by the occurrence of strong adverse events, notably hepatotoxicity, even though these antibodies have exhibited tremendous promise in in vivo tumor models. Efforts are currently underway to develop a new generation of agonist antibodies and recombinant proteins with modified effector functions that can harness the potent T-cell modulation properties of 4-1BB while mitigating adverse effects. In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy.

Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4.
https://pubmed.ncbi.nlm.nih.gov/38172595/